Amyloid Cascade Hypothesis

Overview

The Amyloid Cascade Hypothesis is a leading model for the pathogenesis of Alzheimer’s disease (AD). It proposes that the accumulation and deposition of amyloid-β (Aβ) peptides in the brain is the primary and initiating event that triggers a sequence of pathological changes, including neurofibrillary tangle formation, neuronal loss, and cognitive decline.

Biological Mechanism

  1. APP Processing: The amyloid precursor protein (APP) is a transmembrane protein. In the “amyloidogenic” pathway, APP is cleaved by β-secretase and γ-secretase to release Aβ peptides (primarily Aβ40 and Aβ42).
  2. Aβ Aggregation: These peptides, especially Aβ42, have a high tendency to aggregate into oligomers and eventually form insoluble amyloid plaques in the extracellular space.
  3. Downstream Effects: The presence of Aβ is hypothesized to trigger:
    • Calcium Dysregulation: Disruption of intracellular calcium homeostasis.
    • Tau Hyperphosphorylation: Activation of kinases that lead to the formation of neurofibrillary tangles.
    • Neuroinflammation: Activation of microglia and astrocytes.
    • Synaptic Dysfunction: Impairment of long-term potentiation (LTP) and synaptic plasticity.

Scientific Consensus

  • Established Fact: Mutations in genes related to Aβ production (APP, PSEN1, PSEN2) cause early-onset familial Alzheimer’s disease.
  • Hypothesis: Aβ is the sole or sufficient trigger for sporadic AD. This is still debated, as many clinical trials targeting Aβ have failed to improve cognitive outcomes in symptomatic patients.
  • Level of Consensus: High for familial AD; moderate and increasingly contested for sporadic AD, leading to refined versions of the hypothesis (e.g., Aβ oligomer hypothesis).

Evidence

  • Genetic Linkage: Trisomy 21 (Down syndrome) and FAD mutations directly link APP gene dosage and processing to AD pathology.
  • Biomarkers: PET imaging and CSF analysis show Aβ deposition precedes cognitive symptoms by decades.